Current Report · Items 7.01, 9.01 · 8-K

Microbot Medical Inc.

MBOTNASDAQEQUITYCurrent

Regulation FD Disclosure

Filed Jul 21, 2026Accepted Jul 21, 2026, 8:30 AM EDTCIK 883975Accession 0001493152-26-034014

Company context

Microbot Medical Inc. (NASDAQ: MBOT) is a pre-commercial stage medical technology company with a vision to improve the quality of care for millions of patients and providers globally. The Company has developed the world’s first single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. Further information about Microbot Medical® is available at http://www.microbotmedical.com.

Current securities

MBOTNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 7.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 7.01Item 7.01 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On July 21, 2026, Microbot Medical Inc. (the “Company”) issued a press release announcing that Harel Gadot, the Company’s CEO, President and Chairman, will be participating at this year’s Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, 2026, in Fort Lauderdale, FL. He will present an overview of the endovascular robotic market and discuss emerging technologies in the peripheral vascular, neurovascular and cardiovascular spaces. The panel will be livestreamed at 10:25 am ET at: https://srs2026.eventscribe.net/SearchByBucket.asp?pfp=Track&bm=Plenary+3%3A+Novel+Robotic+Technologies+and+Applications+in+Digital+Surgery. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference. The information in this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in this Item 7.01 or Exhibit 99.1. Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description Number ────────────────────────────────────────────────────────────────────────────────────── 99.1 Press Release 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

Filed exhibits (1)

EX-99.1 (by filename) ex99-1.htm

EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Microbot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting Company CEO has been a featured presenter at several recent industry events on the emergence of endovascular robotics as expert speaking opportunities raising profile of the Company throughout medtech market HINGHAM, Mass., July 21, 2026 - Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY ® Endovascular Robotic System, will be participating at this year’s Society of Robotic Surgery (SRS) annual meeting, being held from July 23-26, in Fort Lauderdale, FL. Last year’s meeting was the first time that endovascular robotics was featured at SRS, and with the Company’s FDA clearance less than a year ago and the growing adoption of the LIBERTY System at leading academic centers in the U.S. for a broad range of peripheral endovascular procedures, the Company believes the continued focus on this segment of the market underscores its increasing importance within the robotic surgery landscape. The panel session, titled: “Neurovascular Robotics,”…

Open exhibit ↗

Get the free weekly BCS email.